About: Ephraim Heller

Facets (new session)
Description
Metadata
Settings
- Rule:
- Inverse Functional Properties:
- "Same As":

About: Ephraim Heller Goto Sponge NotDistinct Permalink

An Entity of Type : yago:Whole100003553, within Data Space : dbpedia.org associated with source document(s)
QRcode icon

http://dbpedia.org/describe/?url=http%3A%2F%2Fdbpedia.org%2Fresource%2FEphraim_Heller

Ephraim Heller is an inventor and entrepreneur, and the current CEO of SynAgile Corporation. SynAgile is developing new therapies for treatment of Parkinson's disease. In 1992, he was the co-founder and first CEO of TheraSense, which went public and was later sold to Abbott Labs for $1.2 billion. He was also co-founder, chairman and CEO of AngioScore and led the product development and FDA approval. AngioScore was acquired in 2014 for $230 million plus milestone payments. Prior to its acquisition, the company sold more than 300,000 AngioSculpt catheters in over 65 countries around the world. He was previously a venture partner at 7 Health Ventures. Heller holds an MBA from Yale School of Management and he has an AB in Physics from Harvard. His father is the engineer Adam Heller.

Attributes	Values
rdf:type	Thing yago:WikicatAmericanInventors yago:WikicatLivingPeople yago:Alumnus109786338 yago:CausalAgent100007347 yago:Creator109614315 yago:Intellectual109621545 yago:Inventor110214637 yago:LivingThing100004258 yago:Object100002684 yago:Organism100004475 yago:Person100007846 yago:PhysicalEntity100001930 yago:WikicatHarvardUniversityAlumni yago:YagoLegalActor yago:YagoLegalActorGeo yago:Scholar110557854 yago:Whole100003553
rdfs:label	Ephraim Heller (en)
rdfs:comment	Ephraim Heller is an inventor and entrepreneur, and the current CEO of SynAgile Corporation. SynAgile is developing new therapies for treatment of Parkinson's disease. In 1992, he was the co-founder and first CEO of TheraSense, which went public and was later sold to Abbott Labs for $1.2 billion. He was also co-founder, chairman and CEO of AngioScore and led the product development and FDA approval. AngioScore was acquired in 2014 for $230 million plus milestone payments. Prior to its acquisition, the company sold more than 300,000 AngioSculpt catheters in over 65 countries around the world. He was previously a venture partner at 7 Health Ventures. Heller holds an MBA from Yale School of Management and he has an AB in Physics from Harvard. His father is the engineer Adam Heller. (en)
dcterms:subject	Living people Year of birth missing (living people) 20th-century American inventors American health care chief executives Harvard University alumni Yale School of Management alumni 21st-century American inventors
Wikipage page ID	34498671 (xsd:integer)
Wikipage revision ID	1107472928 (xsd:integer)
Link from a Wikipage to another Wikipage	Living people Year of birth missing (living people) 20th-century American inventors American health care chief executives Harvard University alumni Yale School of Management alumni Adam Heller Parkinson's disease 21st-century American inventors Yale School of Management Abbott Labs
Link from a Wikipage to an external page	https://web.archive.org/web/20120117034504/http:/www.abbottdiabetescare.com/about-us.html https://www.nytimes.com/2004/01/14/business/the-markets-stocks-bonds-corporate-earnings-jitters-send-shares-modestly-lower.html%3Fscp=4&sq=%22therasense%22&st=cse https://www.sec.gov/Archives/edgar/data/1800/000104746904005498/a2127912z10-k.htm http://investing.businessweek.com/research/stocks/private/person.asp%3FpersonId=11340863&privcapId=47695348&previousCapId=24160&previousTitle=ABAXIS%20INC
sameAs	Ephraim Heller Ephraim Heller Ephraim Heller Ephraim Heller
dbp:wikiPageUsesTemplate	dbt:Authority_control dbt:Cleanup_bare_URLs dbt:Orphan dbt:Reflist
has abstract	Ephraim Heller is an inventor and entrepreneur, and the current CEO of SynAgile Corporation. SynAgile is developing new therapies for treatment of Parkinson's disease. In 1992, he was the co-founder and first CEO of TheraSense, which went public and was later sold to Abbott Labs for $1.2 billion. He was also co-founder, chairman and CEO of AngioScore and led the product development and FDA approval. AngioScore was acquired in 2014 for $230 million plus milestone payments. Prior to its acquisition, the company sold more than 300,000 AngioSculpt catheters in over 65 countries around the world. He was previously a venture partner at 7 Health Ventures. Heller holds an MBA from Yale School of Management and he has an AB in Physics from Harvard. His father is the engineer Adam Heller. (en)
prov:wasDerivedFrom	wikipedia-en:Ephraim_Heller?oldid=1107472928&ns=0
page length (characters) of wiki page	3304 (xsd:nonNegativeInteger)
foaf:isPrimaryTopicOf	wikipedia-en:Ephraim_Heller
is foaf:primaryTopic of	wikipedia-en:Ephraim_Heller

Faceted Search & Find service v1.17_git139 as of Feb 29 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 08.03.3330 as of Mar 19 2024, on Linux (x86_64-generic-linux-glibc212), Single-Server Edition (61 GB total memory, 51 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software